key: cord-0719079-yoh4frlg
authors: Mittal, Juhi; Ghosh, Amerta; Bhatt, Surya Prakash; Anoop, Shajith; Ansari, Irshad Ahmad; Misra, Anoop
title: High prevalence of post COVID-19 fatigue in patients with type 2 diabetes: A case-control study
date: 2021-09-24
journal: Diabetes Metab Syndr
DOI: 10.1016/j.dsx.2021.102302
sha: 10f10102e1cd7abe10ce53fe6a2ffb695f8c1979
doc_id: 719079
cord_uid: yoh4frlg

BACKGROUND: Post COVID-19 syndrome (PCS) has emerged as a major roadblock in the recovery of patients infected with SARS-CoV-2. Amongst many symptoms like myalgia, headache, cough, breathless; fatigue is one of the major symptoms which makes the patient severely debilitated. Research on PCS, in particular fatigue, in patients with diabetes has not been done. METHODOLOGY: In this prospective study, we included patients with type 2 diabetes (T2D) who had COVID-19 infection (mild to moderate severity), and matched T2D patients who did not suffer from COVID-19 infection. Demography, anthropometry, glycemic measures, treatment, COVID-19 infection details were recorded. Symptoms were scored using Chalder Fatigue Scale (reported as fatigue score, FS) and handgrip strength (in kg) was recorded by Jamar Hydraulic Hand Dynamometer. RESULTS: A total of 108 patients were included (cases, 52, controls, 56). Both groups were matched for age, duration of diabetes, BMI, TSH and vitamin D levels. T2D patients with COVID-19 infection had significant more fatigue when compared with patients without COVID-19 infection but comparable handgrip strength. Furthermore, patients with T2D with previous COVID-19 infection and who had FS >4 have had significant higher inflammation markers during acute illness, and post COVID-19, had increased post prandial blood glucose levels, lost more weight, had reduced physical activity and significantly lower handgrip strength as compared to those with FS <4. CONCLUSION: Patients with T2D who had COVID-19 infection as compared to those without had significantly more fatigue after the acute illness, and those with higher fatigue score had reduced handgrip strength indicating sarcopenia. Rehabilitation of those with FS >4 after acute infection would require careful attention to nutrition, glycemic control and graduated physical activity protocol.

We compared patients with T2D who had COVID-19 infection, and matched T2D patients who did not suffer from COVID-19 infection.

Patient with T2D who had COVID-19 infection had significantly more fatigue, weight loss and reduced exercise capacity, but showed preserved handgrip strength.

3. Patients with T2D and COVID-19 having higher fatigue had loss of weight, high inflammatory markers and reduced handgrip strength.

A surge of COVID-19 in India during April-May 2021 has accentuated several health issues during recovery. Post COVID-19 syndrome (PCS, commonly known as "Long COVID") comprises of myriad symptoms referrable to all systems of body and not explained by any alternative diagnosis (1) . The symptoms include fatigue, myalgias, cough, sleepiness, headache etc. (2) . Among these, fatigue is predominant, present afterwards in both hospitalized and non-hospitalized patients (3, 4) . More specifically, the prevalence of fatigue following hospitalization for COVID-19 ranges from 52 to 72% at 1-6 months after hospital discharge (3, 5) . Fatigue and associated symptoms decrease quality of life and interferes with normal working capacity.

Such post-viral fatigue syndrome resembles 'chronic fatigue syndrome' when it persists (6) . This has been seen in many other viral illnesses Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS), and Influenza (H1N1). Fatigue may persist for long periods and is largely independent of their pulmonary function and exercise capacity (7) . During follow-up of survivors of other coronaviruses, such as those who suffered from SARS, 64% reported fatigue at 3 months, 54% at 6 months, and 60% at 12 months (8) . A recent study comprising a combination of admitted patients and outpatients of SARS-CoV-2 infection showed that overall, 52% had fatigue (9) as assessed with the Chalder Fatigue Scale (CFQ-11)(10).

Diabetes complicates course of COVID-19 and results in excess morbidity and mortality (11) . Presence of diabetes also influences PCS via various pathophysiological mechanisms (1). Further, diabetes poses challenges in recovery of PCS. There have been no studies pertaining to fatigue, as a part of PCS, in patients with diabetes. We hypothesized that patients with type 2 diabetes (T2D) are at higher risk of suffering from post-COVID-19 fatigue as compared to those who did not suffer from COVID-19. The objective of our study was to determine the prevalence of fatigue using the CFQ-11 and handgrip strength (as a surrogate marker for sarcopenia) in patients with T2D after COVID-19 infection, and to compare with patient with diabetes without history of COVID-19 infection.

Study design: This was a prospective study of patients with T2D who came to outpatient department of tertiary care diabetes hospital (Fortis CDOC Hospital for Diabetes and Allied Sciences, New Delhi). Cases comprised of a. patients with diabetes who had COVID-19 infection proved with reverse transcriptase polymerase chain reaction, and b. matched patients who did not suffer from COVID-19 infection. Patients with COVID-19 who suffered from mild symptoms and underwent home quarantine or had moderate to severe symptoms and were hospitalized or intensive care unit were included. All patients having history of any other prolonged illness other than COVID-19 and severe complications of diabetes were excluded from the study.

We used worksheet that contained background information on demographics, height, weight, duration of diabetes, details of COVID-19 illness, current symptoms, changes in weight, diet drugs and insulin before and after COVID-19, and symptoms including fatigue. For patients without COVID-19 infection all data except COVID information were recorded.

Fatigue Assessment: We used a predesigned worksheet to analyze the patient's fatigue using CFQ-11 (10) . The 11-item questionnaire is divided into two components: one that measures physical fatigue (questions 1-7) and one those measures mental fatigue (questions [8] [9] [10] [11] . Each of the 11 items were answered on a 4-point scale ranging from the asymptomatic to maximum symptomology, such as 'Better than usual', 'No worse than usual', 'Worse than usual' and 'Much worse than usual'. Conventionally, fatigue case-status (fatigued vs. non-fatigued) is defined using this scale with a cut-off <4 vs. ≥4. These have been termed as fatigue score (FS).

Handgrip Strength: This was performed with standard Jamar Hydraulic Hand Dynamometer (Sammons Preston, IL, USA) which estimates the muscle strength primarily generated by the flexor muscles of the hand and the forearm. This dynamometer displays handgrip force in both pounds and kilograms, with a maximum of 200 lb. (90 kg). It has a peak-hold needle that automatically retains the highest reading until reset. This test is isometric, with no perceptible motion of the handle, regardless of the grip strength applied. The participants were encouraged to produce their maximal grip strength. Three trials were recorded, consisting of a 2-4-second maximal contraction, with a 30-second rest period between each trial. The average of the three readings was taken. 

Data were checked for normality. Continuous variables were summarised as Mean +/ -SD using Student's t test or median using Mann Whitney test. Categorical data were summarised as frequency using Person's Chi square test. The P value < 0.05 was considered statistically significant. Statistical analysis was performed using STATA software (Version 14.2, Stata Corp, College Station, Texas USA)

A total of 108 patients were included in the study (cases, 52, controls, 56). Both the groups were matched for age, duration of diabetes, BMI. Further matching was done for common factors which may cause fatigue; 25(OH)D and TSH levels. Average time of presentation of patients post COVID was 92 (range 32-262) days Overall, 31 (58.4%) patients with COVID-19 infection underwent home quarantine, and 22 (41.5%) patients were hospitalized. Out of hospitalized patients 14 (63%) were admitted in ward and 8 (36%) were admitted in intensive care unit, 3 patients required ventilator support, 3 required Bi PAP support and 2 required oxygen support. In T2D and COVID-19 group, 30 patients (57.6%) were given corticosteroids (a combination of oral and injectable corticosteroids). The baseline characteristics of both the groups are listed in table 1. There was a significant increase in PPBG in patients who suffered from COVID-19. On FS, 53% of patient who suffered from COVID-19 infection had significant fatigue whereas 37% of had it in those without COVID. There was no difference in handgrip strength between the two groups.

Patients with COVID-19 infection and FS > 4 had more symptoms of shortness of breath and weakness and had more weight loss. These patients also had significantly higher TSH, lower serum albumin, higher PPBG, IL-6, and ferritin levels when compared with patients with COVID-19 infection having FS4. Handgrip strength was also significantly reduced in patients with COVID-19 infection with high fatigue vs low FS (Table 2) . Those with higher FS also had significantly reduced physical activity as compared to those with lower score. Specifically, exercise capacity (level walk) was significantly reduced in patients with COVID-19 irrespective of hospitalization and home quarantined treatment. In hospitalized patients it reduced from 37.63±16.23 to 21.31±11.23 mins/day (p value 0.05) and in patients who were home quarantined it reduced from 28.78±4.15 to 24.39±12.32 mins/day (p value 0.04)

This research shows that patients with T2D who had COVID-19 have higher fatigue than those who did not have COVID-19. There was no difference in the two groups in handgrip strength, suggesting major J o u r n a l P r e -p r o o f sarcopenia had not occurred. Further, among patients who suffered from COVID-19, those who had more FS, as compared to lower FS score, had had more symptoms, weight loss, higher levels of inflammatory markers during infection and lesser handgrip strength. These data become more important since these patients were matched for BMI, duration of diabetes, and factors that could contribute to fatigue and morbidities i.e., thyroid functions, vitamin D (12) and serum albumin status. Limitations of our study includes inability to do autonomic function and muscle enzyme levels. It is important to note that while many studies have looked at PCS and fatigue, no study has researched this question on exclusive cohort of patients with diabetes.

While fatigue has been seen in considerable number of patients after COVID-19, its pathogenesis is largely unknown (1). One of the key factors is inflammation induced by COVID-19, which can cause 'accelerated ageing' of the muscles (13) leading to sarcopenia. In our study, those patients who had high levels of inflammatory markers during COVID-19 had high FS. In a previous study, 35% of the hospitalised patients who suffered from COVID-19 was characterised as malnourished, mainly caused by considerable weight loss and 73% had high risk of sarcopenia (14) . Immobility during hospital stay is further detrimental to skeletal muscle. This could be further prolonged because of secondary infections (15) . Hypoxia induced by major COVID-19 pneumonia and subsequent fibrosis could also lead to muscle fatigue. Besides these psychological stress and depression, often seen post COVID-19 could also lead to fatigue (1). Prolonged corticosteroid use (16) and electrolyte disorders (e.g., hypokalaemia) could exacerbate muscle weakness. Uncontrolled glycemic status of our patients post COVID-19 could have also contributed to fatigue (Table 2) .

Nutritional deficiencies could be a major concern after discharge in COVID-19 patients. Patients may have poor oral intake due to disease, drugs or lack of taste and smell, which may lead to decreased protein levels and other nutrients essential to muscle metabolism. It is important to note that both the groups in our study had adequate and comparable albumen levels. About 61% had weight loss, and 14.6% were undernourished in a small cohort of COVID-19 patients at discharge (17) . Among these the following deficiencies were noted; 19.5% hypoalbuminemia, 19.5% hypocalcemia, 34.1% anemia, 12.2% hypomagnesemia and 51.2% deficiency in vitamin D (17) . Despite these problems, nutrition advise has not been given adequately to the patients (14) . In our study, those patients with T2D and previous COVID-19, and high FS, showed decreased serum albumin levels.

All the above discussed factors are operative to a larger extent in elderly, and those with chronic diseases, including diabetes. Sarcopenia is common in patients with diabetes and increases with age. It is more common in Asians vs. non-Asians, and Indians may be more predisposed to it (18) . Other contributory factors to sarcopenia include gender (more in females), body mass index (higher with low BMI), disease duration (increase with duration of diabetes), glycemic control (greater with poorer control), presence of microvascular or macrovascular complications, nutritional status, etc. (19). Occurrence of severe COVID-19 should be added as another factor, and such sarcopenia would lead to fatigue. In our study, those who had COVID-19, and had fatigue score >4 also lost more weight and had decrease in physical activity. These patients also had reduced handgrip strength.

One of the causes of PCS has been hypothesised as 'dysautonomia', It has been shown that participants with PCS and fatigue had dysregulation of heart rate variability (20) . The authors stated that such dysautonomia could lead to fatigue and hypoxia. It is to be noted that autonomic dysfunction is common in longstanding and uncontrolled diabetes, and post COVID-19 dysautonomia may augment it. In our study, we did not perform autonomic function tests.

Management of post COVID-19 fatigue should be multidisciplinary including physician, psychological counsellor, nutritionist, and physical therapy expert (1) . Blood glucose and blood pressure should be optimally controlled (21, 22) . Special care must be taken regarding nutrition; protein and vitamin supplements should be used as per requirement (23). Vitamin D, calcium, iron, magnesium and C supplementation may help. In a review, data from nine clinical studies showed significant decrease in fatigue scores in the group receiving vitamin C group vs. control group (24) . Exercise and physiotherapy should be started early as it may benefit not only fatigue but cardiovascular, pulmonary and mental fitness (1) . In cases of marked weight loss, it may be advisable to withhold SGLT2i and GLP-1 receptor analogs.

Funding: There is no source of funding for this study.

Conflict of interest: Authors declare no conflict of interests.

Author Contribution: AM conceived the study, reviewed, and edited the manuscript. AG conducted the study and wrote the manuscript, JM, IA conducted the study, SA and SP analysed, interpreted the data, and contributed to discussion. AM is the guarantor for this manuscript. 

Long COVID") and Diabetes: Challenges in Diagnosis and Management

COVID-19 rapid guideline: managing the long-term effects of COVID-19. National Institute for Health and Care Excellence: Clinical Guidelines

Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation

Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study

6-month consequences of COVID-19 in patients discharged from hospital: a cohort study

Chronic fatigue syndrome, the immune system and viral infection

Chronic widespread musculoskeletal pain, fatigue, depression and disordered sleep in chronic post-SARS syndrome; a case-controlled study

One-year outcomes and health care utilization in survivors of severe acute respiratory syndrome

Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection

Development of a fatigue scale

Contentious issues and evolving concepts in the clinical presentation and management of patients with COVID-19 infectionwith reference to use of therapeutic and other drugs used in Co-morbid diseases (Hypertension, diabetes etc)

Impact of the vitamin D deficiency on COVID-19 infection and mortality in Asian countries

Post-COVID-19 acute sarcopenia: physiopathology and management

Poor nutritional status, risk of sarcopenia and nutrition related complaints are prevalent in COVID-19 patients during and after hospital admission

Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India

Steroid use during COVID-19 infection and hyperglycemia -What a physician should know

Nutritional status assessment in patients with Covid-19 after discharge from the intensive care unit

Epidemiology and determinants of type 2 diabetes in south Asia

A Narrative Review on Sarcopenia in Type 2 Diabetes Mellitus: Prevalence and Associated Factors

Clinical characterization of dysautonomia in long COVID-19 patients

Majorly Resurgent and Uncontrolled Diabetes During COVID19 Era, and in the Future Can Be Contained in India

Clinical considerations in patients with diabetes during times of COVID19: An update on lifestyle factors and antihyperglycemic drugs with focus on India

Feasibility of Vitamin C in the Treatment of Post Viral Fatigue with Focus on Long COVID, Based on a Systematic Review of IV Vitamin C on Fatigue